Nature Communications (Dec 2021)
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
- Joris L. Vos,
- Joris B. W. Elbers,
- Oscar Krijgsman,
- Joleen J. H. Traets,
- Xiaohang Qiao,
- Anne M. van der Leun,
- Yoni Lubeck,
- Iris M. Seignette,
- Laura A. Smit,
- Stefan M. Willems,
- Michiel W. M. van den Brekel,
- Richard Dirven,
- M. Baris Karakullukcu,
- Luc Karssemakers,
- W. Martin C. Klop,
- Peter J. F. M. Lohuis,
- Willem H. Schreuder,
- Ludi E. Smeele,
- Lilly-Ann van der Velden,
- I. Bing Tan,
- Suzanne Onderwater,
- Bas Jasperse,
- Wouter V. Vogel,
- Abrahim Al-Mamgani,
- Astrid Keijser,
- Vincent van der Noort,
- Annegien Broeks,
- Erik Hooijberg,
- Daniel S. Peeper,
- Ton N. Schumacher,
- Christian U. Blank,
- Jan Paul de Boer,
- John B. A. G. Haanen,
- Charlotte L. Zuur
Affiliations
- Joris L. Vos
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Joris B. W. Elbers
- Department of Radiation Oncology, Erasmus University Medical Center
- Oscar Krijgsman
- Neogene Therapeutics
- Joleen J. H. Traets
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute
- Xiaohang Qiao
- Division of Tumor Biology & Immunology, The Netherlands Cancer Institute
- Anne M. van der Leun
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute
- Yoni Lubeck
- Department of Pathology, The Netherlands Cancer Institute
- Iris M. Seignette
- Department of Pathology, The Netherlands Cancer Institute
- Laura A. Smit
- Department of Pathology, The Netherlands Cancer Institute
- Stefan M. Willems
- Department of Pathology and Medical Biology, Groningen University Medical Center
- Michiel W. M. van den Brekel
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Richard Dirven
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- M. Baris Karakullukcu
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Luc Karssemakers
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- W. Martin C. Klop
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Peter J. F. M. Lohuis
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Willem H. Schreuder
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Ludi E. Smeele
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Lilly-Ann van der Velden
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- I. Bing Tan
- Department of Otorhinolaryngology Head and Neck Surgery, Maastricht University Medical Center+
- Suzanne Onderwater
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- Bas Jasperse
- Department of Radiology, Amsterdam University Medical Center location VUmc
- Wouter V. Vogel
- Department of Nuclear Medicine, The Netherlands Cancer Institute
- Abrahim Al-Mamgani
- Department of Radiation Oncology, The Netherlands Cancer Institute
- Astrid Keijser
- Department of Biometrics, The Netherlands Cancer Institute
- Vincent van der Noort
- Department of Biometrics, The Netherlands Cancer Institute
- Annegien Broeks
- Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute
- Erik Hooijberg
- Department of Pathology, The Netherlands Cancer Institute
- Daniel S. Peeper
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute
- Ton N. Schumacher
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute
- Christian U. Blank
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute
- Jan Paul de Boer
- Department of Medical Oncology, The Netherlands Cancer Institute
- John B. A. G. Haanen
- Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute
- Charlotte L. Zuur
- Department of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-021-26472-9
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Immune checkpoint blockade has become standard care for patients with recurrent metastatic head and neck squamous cell carcinoma (HNSCC). Here the authors present the results of a non-randomized phase Ib/IIa trial, reporting safety and efficacy of neoadjuvant nivolumab monotherapy and nivolumab plus ipilimumab prior to standard-of-care surgery in patients with HNSCC. .
